Email this article THE WAYS TO OPTIMIZE DRUG SAFETY MONITORING SYSTEM: PROFESSIONAL AND ETHIC EDUCATION
- Authors: Smuseva O.N1, Kamyshova D.A1, Smusev A.Y.2
-
Affiliations:
- Volgograd state medical university
- Company «Infocom»
- Issue: Vol 6, No 2 (2013)
- Pages: 18-20
- Section: Articles
- URL: https://medbiosci.ru/2070-1586/article/view/54902
- ID: 54902
Cite item
Full Text
Abstract
The main source of information about adverse drug reactions (ADR) is a spontaneous reporting system based on an active ADR registration carried out by practitioners. Our study demonstrated the effectiveness of schools-workshops for physicians which were devoted to the ways of improving the work of Regional Drug Safety Monitoring centers and ethic aspects of ADR monitoring.
Full Text
##article.viewOnOriginalSite##About the authors
O. N Smuseva
Volgograd state medical university
Email: son74@mail.ru
Ph.D., chair of clinical pharmacology
D. A Kamyshova
Volgograd state medical universityThe intership Doctor chair of clinical pharmacology
A. Yu Smusev
Company «Infocom»The System Engineer
References
- Федеральный закон Российской Федерации от 12.04. 2010 N 61-ФЗ «Об обращении лекарственных средств» // Российская газета. 2010. №5157.
- Петров В.И. Учить биоэтике будущего//Биоэтика.-2012.-№2(10). -С.4-6.
- Петров В.И., Смусева О.Н., Соловкина Ю.В. Совершенствование мониторинга безопасности лекарственных средств в регионах на примере Волгоградской области//Профилактическая и клиническая медицина. 2011. Т.3, № 40. С.73-76.
- Смусева О.Н. Регистрация нежелательных лекарственных реакций в первичной медицинской документации/О.Н.Смусева , О.В.Шаталова, Ю.В.Соловкина, Н.А.Воронкова//Вестник ВолГМУ. - 2011. - №4(40). - С.37-39.
- How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme/Krska J. [et. al.]// Drug Saf 2011. Vol. 34, №5. P. 429 - 36.
- Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis/Harpaz R. [et. al.]// Clin Pharm Ther. 2012. Vol. 91, № 6. P.1010-1021.
- Biclustering of adverse drug events in the FDA’s spontaneous reporting system/ Harpaz R. [et. al.] //Clin. Pharmacol. Ther. 2011. Vol. 89. P.243-250.
- Basch E. The Missing Patient Voice in Drug-Safety Reporting// N. Engl. J. Med. 2010. Vol. 362, №10. P.865-869.
Supplementary files
